This message contains images. If you don't see images, click here to view.
Click
here to advertise in this news brief.
|
|
|
|
Now accepting abstracts for CEOT 2015
The Cutting Edge of Transplantation
Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies
AST
Feb. 5-7, 2015
Sheraton Wild Horse Pass – Chandler, Arizona
Share your research with experts in transplantation. Submit your basic, clinical or translational abstract now! Make plans to attend this high-energy, intimate meeting where expert clinicians, leading diagnosticians, and world class scientists will address the field’s cutting edge challenges together with an engaged audience. This year’s CEOT will feature sessions on:
- A Critical Review of Cell Therapies
- Whatever Happened to Gene Therapy?
- Organ Repair and Regeneration, and Organ Generation
- Drug Development and Rediscovering Pathways
Click here to submit your basic, clinical or translational abstract.
|
UPCOMING EVENTS IN TRANSPLANTATION
|
Transplant Quality Institute, by the American Foundation for Donation and Transplantation
AST
With the emphasis on transplant programs’ quality and outcomes, the AMFDT assembled this three-day conference on Focused QAPI. The conference is designed to meet the unique needs of transplant professionals who need education about the new CMS Focused QAPI, and features keynote speaker Thomas Hamilton of CMS. Register and view the program at www.amftd.org.
Discounted registration ends soon
AST
ESOT + AST Joint Meeting
Personalized Transplantation: From New Diagnostics to New Therapeutics
Oct. 17-19, 2014
Madrid, Spain
Register by Sept. 7 to take advantage of early registration and a discounted rate. Join the ESOT and AST in beautiful Madrid, Spain as together we explore:
- New Options to Improve Immunosuppressive Therapy
Belatacept, Anti CD40 trial (ASKP1240), Anti- IL-6 and Tacrolimus formulations
- Novel Diagnostics
Donor DNA - Biomarker of Graft Injury, In vivo Live Imaging of the Immune Response and Tolerance Profile
- Novel Targets for Immunosuppression
B-cells, Plasma Cells and Complement
- Personalized Medicine: Technique and Technology
Sequencing for TCR Repertoire, Pharmacogenetics, Epigenetics and Mixed Chimerism
- Cellular Strategies to Optimize Long Term Outcomes
T-regs, Mesenchymal Cells, Facilitator Cells
Click here to learn more about this enlightening meeting, or view the full program.
|
Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
LEARN MORE
|
|
To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE
|
|
Association between liver transplant center performance evaluations and transplant volume
American Journal of Transplantation
There has been increased oversight of transplant centers and stagnation in liver transplantation nationally in recent years. This study hypothesized that centers that received low performance (LP) evaluations were more likely to alter protocols, resulting in reduced rates of transplants and patients placed on the waiting list. It evaluated the association of LP evaluations and transplant activity among liver transplant centers in the United States using national Scientific Registry of Transplant Recipients data (January 2007 to July 2012).
Kidney Donor Risk Index (KDRI) fails to predict kidney allograft survival in HIV (+) recipients
Transplantation
This study used the United Network of Organ Sharing Standard Transplant Analysis and Research Files (STAR files) to investigate the utility of the Kidney Donor Risk Index (KDRI) versus delayed graft function (DGF) to predict graft survival in the HIV (+) kidney transplant recipients. Individual matching (one case to five controls) was used to investigate predictive ability of the KDRI for graft survival in HIV (+) recipients (cases) as compared to HIV (−) recipients (controls) leaving 400 HIV (+) recipients matched with 1,904 HIV (−) recipients.
PRODUCT SHOWCASE
 |
|
The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
|
|
National assessment of early biliary complications after liver transplantation: Economic implications
Transplantation
Despite improvement in surgical technique and medical management of liver transplant recipients, biliary complications remain a frequent cause of posttransplant morbidity and graft loss. Biliary complications require potentially expensive interventions including radiologic procedures and surgical revisions. A national data set linking transplant registry and Medicare claims data for 12,803 liver transplant recipients was developed to capture information on complications, treatments, and associated direct medical costs up to 3 years after transplantation.
Chronic kidney disease and associated mortality after liver transplantation – A time-dependent analysis using measured glomerular filtration rate
Journal of Hepatology
The accuracy of creatinine-based estimated GFR (eGFR) in assessing the prevalence of chronic kidney disease (CKD) and associated mortality after liver transplantation (LTx) is unknown. Using measured GFR (mGFR) by iothalamate clearance, we determined the prevalence of the entire spectrum of renal dysfunction and the impact of CKD on mortality after LTx.
Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy
Liver Transplantation
There are complex risk-benefit tradeoffs with different transplantation strategies for end-stage liver disease patients on renal support. Using a Markov discrete-time state transition model, we compared survival for this group with 3 strategies: simultaneous liver-kidney (SLK) transplantation, liver transplantation alone (LTA) followed by immediate kidney transplantation if renal function did not recover, and LTA followed by placement on the kidney transplant wait list. Patients were followed for 30 years from the age of 50 years.
The preferences and perspectives of nephrologists on patients' access to kidney transplantation: A systematic review
Transplantation
This study aimed to describe nephrologists' attitudes to patients' access to kidney transplantation. Studies that assessed nephrologists' perspectives toward patient referral, screening, and eligibility for kidney transplantation were synthesized. Twenty-four studies were included. Patients with comorbidities, were nonadherent, of older age, ethnic minorities, or low socioeconomic status were less likely to be recommended.
The current state of intestine transplantation: Indications, techniques, outcomes and challenges
American Journal of Transplantation
Intestine transplantation is the least common form of organ transplantation in the United States and often deemed one of the most difficult. Patient and graft survival have historically trailed well behind other organ transplants. Over the past 5–10 years registry reports and single center series have demonstrated improvements to patient survival after intestinal transplantation that now match patient survival for those without life-threatening complications on parenteral nutrition.
Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: A systematic review and meta-analysis
Journal of Hepatology
Baseline 25-hydroxyvitamin D [25(OH)D] level has recently been reported to be an independent predictor of sustained virologic response (SVR) to treatment with pegylated interferon (PEG-IFN) plus ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. However studies have yielded inconsistent results, thus we conducted a systematic review and meta-analysis to clarify any association between baseline 25(OH)D level and SVR to HCV therapy.
Missed last week's issue? See which articles your colleagues read most.
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
